Key Points
Brookfield Corporation trades at a discount to its assets and holdings, and its value could continue to compound in the coming years.
SSR Mining remains one of the best ways to capitalize on rising precious metals prices.
Teva Pharmaceuticals is pivoting from generic drugs to branded specialty treatments.
Numerous factors are affecting the stock market right now. However, many long-term opportunities remain. Some stocks benefit from current trends, whether they be rising spot gold prices or accelerating adoption of generative artificial intelligence (AI).
There are also stocks benefiting from trends unaffected by the macroeconomic and geopolitical backdrop. While these stocks are not necessarily immune to near-term market volatility, buying them today could prove very profitable in the long run.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Three stocks that come to mind are Brookfield Corporation(NYSE: BN), SSR Mining(NASDAQ: SSRM), and Teva Pharmaceuticals(NYSE: TEVA). Even if you only have $1,000 today to put toward a long-term portfolio, each stock is a great choice.
Image source: Getty Images.
Brookfield is an undervalued compounding machine
Canada-based holding company Brookfield Corporation may seem complicated.In addition to its majority stake in its well-known Brookfield Asset Management(NYSE: BAM) subsidiary, Brookfield also holds interests in a variety of public and privately held investment vehicles managed by the asset management unit.
Brookfield has also vastly expanded its insurance operations, focusing on profiting from the long-term investment of its insurance assets, similar to Berkshire Hathaway's objective when it comes to owning insurance companies . For years, Brookfield's management has noted that the company trades at a discount to the underlying value of its holdings.
This valuation discount persists and could continue to do so. Even so, as management also anticipates more than 20% earnings growth over the next five years, such growth could help close the valuation gap, resulting in strong price appreciation.
SSR Mining could thrive in uncertain times
As geopolitical tensions escalate, spot gold prices spiked yet again. That's good news for those holding physical gold in their portfolios, but for those owning precious metals stocks, higher gold prices could have an outsized impact on their investments.
That's the bull case for SSR Mining. The production-stage gold mining company's fiscal performance improved substantially last year, thanks to gold surging from $3,000 to over $5,000 per ounce. In 2025, this high-double-digit increase in gold prices resulted in more than a sevenfold adjusted earnings growth
Following the latest gold spike, SSR's stock price has hit new highs. However, don't assume shares have topped out. Multiple factors point to gold remaining at elevated prices, if not moving higher. If high gold prices are here to stay, SSR Mining could rise on both higher earnings and valuation expansion.
Currently, the stock trades for less than 9 times forward earnings, while other mining stocks such as Barrick Mining trade at forward multiples in the mid-teens .
Teva's transformation is still unfolding
Israel-based Teva Pharmaceuticals has been a generic drugmaker. In recent years, the company has pivoted to become a branded pharmaceutical company, especially in specialty drugs and treatments.
Teva's generics business is experiencing little to no growth, but its branded drug business is growing at a mid-double-digit clip. As more of the company's drug pipeline advances through clinical trials and regulatory approval, Teva should remain positioned to sustain steady sales and profitability growth.
This growth, along with the move from generic to branded products, could lead to a further reassessing the value of shares. Teva currently trades for 12.5 times forward earnings, but a mid-teens forward multiple could be warranted, given the valuation of other faster-growing pharmaceutical stocks.
Should you buy stock in Brookfield Corporation right now?
Before you buy stock in Brookfield Corporation, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Brookfield Corporation wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $534,817!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,912!*
Now, it’s worth noting Stock Advisor’s total average return is 964% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 6, 2026.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Brookfield, Brookfield Asset Management, and Brookfield Corporation. The Motley Fool has a disclosure policy.
